Illumina has launched its TruSeq Amplicon — Cancer Panel, which targets 35 kilobases of mutational hotspots from 48 known cancer genes with 212 amplicons. The assay is multiplexed, can detect mutations below five percent frequency, and utilizes the same chemistry as Illumina's other TruSeq reagent kits. The assay has been optimized for the MiSeq and works on formalin-fixed, paraffin-embedded tissue, according to the company.
BGI has expanded its sequencing services to include sequencing from formalin-fixed paraffin-embedded tissue from low-input DNA, down to 200 nanograms. According to BGI, its researchers have optimized FFPE DNA library construction to enable the lower inputs.
FlexGen has launched a gene searcher tool, which allows researchers and clinicians to search for predefined FleXelect kits that target their genes of interest for next-gen sequencing.